on osteosarcoma, researchers coupled Exo-MEG3 with a tumor-targeting cRGD peptide, which demonstrated precise tumor-targeting ability and enhanced anti-tumor effects in an osteosarcoma model (122). Here, MEG3 is linked to osteosarcoma.